A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
University Health Network, Toronto
National Cancer Institute (NCI)
Children's National Research Institute
Memorial Sloan Kettering Cancer Center
Eastern Cooperative Oncology Group
National Institutes of Health Clinical Center (CC)
Novartis